Table 1 Patients’ characteristics according to the response to immunoglobulin infusion (N = 157)
|  | Resistant (N = 45) N (%) | Responder (N = 112) N (%) | p |
|---|---|---|---|
Demographics | |||
 Sex (M/F) | 24/21 | 68/44 | .36 |
Age | 31 [24–40] | 31 [27–36] | .96 |
 < 12 months | 13 (29) | 22 (20) | .39 |
 12–23 months | 7 (16) | 34 (30) | .10 |
 ≥ 24 months | 25 (55) | 56 (50) | .47 |
Clinics | |||
 Fever length before Ig (days) | 7 [5–8] | 7 [6–8] | .33 |
 Lymphadenopathy | 18 (40) | 47 (42) | .72 |
 Rash | 39 (87) | 91 (81) | .63 |
 Conjunctivitis | 39 (87) | 76 (68) | .03 |
 Enanthem | 33 (73) | 89 (79) | .67 |
 Modification of the extremities | 18 (40) | 51 (46) | .47 |
 Fever length after Ig (hours) | 60 [56–64] | 24 [21–36] | < 10 −10 |
Biology | |||
 Neutrophils (%) | 70 [66–74] | 65 [62–69] | .17 |
 Platelet count (G/L) | 434,900 [375,140-494,680] | 392,000 [361,860-421,420] | .31 |
 Hemoglobin (g/dl) | 10.4 [9.6–10.4] | 10.7 [10.4–10.9] | .60 |
 CRP (mg/L) | 182 [159–207] | 145 [131–160] | .01 |
 ΔCRP (%) | 41 [30–52] | 61 [56–66] | .0004 |
 ASAT (UI/L) | 46 [39–54] | 60 [44–74] | .32 |
 ALAT (UI/L) | 55 [42–69] | 76 [54–98] | .73 |
 Bilirubin (μmol/L) | 10 [6–14] | 12 [8–15] | .91 |
 LDH (UI/L) | 781 [611–950] | 1442 [1073-1810] | .62 |
 Albumin (g/L) | 23 [21–25] | 26 [25–27] | .16 |
 Sodium (mmol/L) | 135 [134–136] | 135 [134–136] | .44 |
Scores | |||
 Kobayashi |  |  | 1 |
  <  5 | 32 (78) | 86 (78) |  |
  ≥ 5 | 9 (22) | 25 (22) |  |
 Egami |  |  | .49 |
  < 3 | 32 (76) | 88 (82) |  |
  ≥ 3 | 10 (24) | 19 (18) |  |
 Sano |  |  | .50 |
  < 2 | 22 (67) | 66 (73) |  |
  ≥ 2 | 11 (33) | 24 (27) |  |
Treatments | |||
 1st dose IV Ig | 45 (100) | 112 (100) | 1 |
 2nd dose IV Ig | 20 (40) | 1 | < 10 −8 |
 Corticosteroids | 17 (39) | 2 (2) | < 10 −8 |
First echocardiogram results | |||
 Normal | 23 (51) | 86 (77) | .002 |
 Abnormal | 22 (49) | 26 (23) | .002 |
 Coronary artery dilatation | 11 (24) | 13 (12) | .05 |
 Pericardial effusion | 7 (16) | 8 (7) | .13 |
 Perivascular brightness of the coronary arteries | 4 (9) | 3 (3) | .10 |
 CAA | 3 (7) | 4 (4) | .40 |
  Small (<  5 mm) | 1 (2) | 2 (2) | 1 |
  Median (5–8 mm) | 1 (2) | 2 (2) | 1 |
  Giant (>  8 mm) | 1 (2) | 0 | .28 |
 Left ventricular dysfunction | 4 (9) | 2 (2) | .05 |
 Mitral insufficiency | 1 (2) | 1 (1) | .48 |
Abnormal late echocardiograms | |||
 6 weeks | 10 (22) | 8 (7) | .01 |
 Coronary artery dilatation | 5 | 2 |  |
 Pericardial effusion | 1 | 0 |  |
 Perivascular brightness of the coronary arteries | 1 | 0 |  |
 CAA | 3 | 6 |  |
  Small (<  5 mm) | 0 | 4 |  |
  Median (5–8 mm) | 2 | 2 |  |
  Giant (>  8 mm) | 1 | 0 |  |
Long-term | 4 (9) | 3 (3) | .10 |
 Coronary artery dilatation | 2 | 0 |  |
 CAA | 2 | 3 |  |
  Small (<  5 mm) | 1 | 3 |  |
  Median (5–8 mm) | 1 | 0 |  |
  Giant (>  8 mm) | 0 | 0 |  |